Early tolerability of Comirnaty vaccine in patients with chronic neurological diseases

Patients with chronic neurological diseases may have predisposing risk factors for severe COVID-19 and should be considered as priority candidates for SARS-CoV-2 vaccination. Nevertheless, the safety of RNA vaccine was evaluated in healthy volunteers or in patients with stable chronic medical condit...

Descripción completa

Detalles Bibliográficos
Autores principales: Budowski, C., Zavanone, C., Thivard, L., Vassilev, K., Dupont, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Masson SAS. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511656/
https://www.ncbi.nlm.nih.gov/pubmed/34654546
http://dx.doi.org/10.1016/j.neurol.2021.05.005
Descripción
Sumario:Patients with chronic neurological diseases may have predisposing risk factors for severe COVID-19 and should be considered as priority candidates for SARS-CoV-2 vaccination. Nevertheless, the safety of RNA vaccine was evaluated in healthy volunteers or in patients with stable chronic medical conditions excluding patients with chronic neurological diseases. We report here the early tolerability of Comirnaty vaccine in 36 patients with chronic neurological diseases and demonstrate good early tolerability, better than found in healthy people in phase 3 trials.

Ejemplares similares